You are here

  • Home
  • Archive
  • Volume 93, Issue Suppl 1
  • J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

Article metrics

Article menu
Download PDFPDF
J: Clinical therapeutics
J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

 

Online download statistics by month:

Online download statistics by month: September 2022 to September 2023

AbstractFullPdf
Sep 202219506
Oct 20225903
Nov 20227203
Dec 20225406
Jan 20234002
Feb 20233601
Mar 20235001
Apr 20232401
May 20234201
Jun 20232800
Jul 20231800
Aug 20233401
Sep 2023800
Total660025